Related Experiment Videos
Benznidazole with CCNU: a clinical phase I toxicity study
International Journal of Radiation Oncology, Biology, Physics
|February 1, 1985
Summary
Benznidazole (BENZO) did not increase toxicity when combined with CCNU in patients. This combination therapy, using standard CCNU doses, shows potential for enhanced cancer treatment without added side effects.
Area of Science:
- Oncology
- Pharmacology
- Clinical Toxicology
Background:
- Benznidazole (BENZO) has demonstrated synergistic cytotoxicity with various drugs, including nitrosoureas, in preclinical models.
- Nitrosoureas are a class of chemotherapy agents used in cancer treatment.
Purpose of the Study:
- To evaluate the safety and toxicity of escalating doses of benznidazole (BENZO) in combination with a standard dose of CCNU.
- To determine if BENZO enhances the gastrointestinal or hematological toxicity of CCNU in cancer patients.
Main Methods:
- An escalating dose toxicity study was conducted on 34 patients.
- Patients received the standard clinical dose of CCNU (130 mg/m2) combined with increasing doses of BENZO (up to 40 mg/kg).
- Toxicity was monitored, focusing on gastrointestinal and hematological parameters.
Main Results:
- No benznidazole (BENZO)-related toxicity was observed within the studied dose range.
- No evidence suggested that BENZO enhanced the gastrointestinal or hematological toxicity of CCNU.
- Benznidazole was administered at doses that affected CCNU pharmacokinetics, suggesting potential for enhanced cytotoxicity as seen in animal studies.
Conclusions:
- The combination of standard-dose CCNU and escalating doses of benznidazole (BENZO) appears safe in patients.
- Benznidazole does not increase the toxicity profile of CCNU at the doses studied.
- Further investigation in a Phase III study is warranted to explore the therapeutic potential of this drug combination.